Freenome

As we look ahead to the new year, we’re sharing a new video that highlights Freenome’s core mission: detecting cancer early, when it’s most treatable, and making screening simple and more widely accessible. Hear directly from our team on the strategic pillars behind our work. You’ll learn how we approach developing our personalized multi-cancer detection platform to seek out a range of cancer-related signals in the blood and evolve as the science advances. You’ll also hear the individual motivation that the personal impact of cancer provides for so many of our employees. Our unified focus as we enter 2026 is the relentless pursuit of building definitive cancer-screening solutions and delivering the critical impact of early cancer detection. Watch the video to see how we are defining the future of cancer screening: https://lnkd.in/gWJ4FBYE

We’re pleased to announce a collaboration with NVIDIA Healthcare to leverage its advanced AI and deep learning to better recognize and analyze complex biological signals in the blood, with the goal of improving early cancer detection. Blood-based cancer screening relies on finding very subtle patterns that can identify disease at its earliest stages. By using NVIDIA’s accelerated computing, Freenome can train AI models faster and on much larger datasets, helping our personalized multi-cancer detection platform learn to distinguish early cancer signals from normal biological noise more effectively. The work is intended to support more accurate and efficient testing as Freenome scales its screening programs, and to enable broader research use of AI tools through secure, de-identified data. Read the full press release here: https://lnkd.in/gUYvY7y7

Freenome will present new data at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco this week. The findings of “Clinical Performance of an Improved Colorectal Cancer (CRC) Screening Blood Test” will be presented by Aasma Shaukat, M.D., M.P.H., professor of medicine at the NYU Grossman School of Medicine and co-lead principal investigator of the PREEMPT CRC Study. The poster session will take place on Saturday, Jan. 10, at 7:00 a.m. PT, where the team will share data from a large, head-to-head validation study evaluating an updated version of Freenome’s SimpleScreen™ CRC blood test. #GI26 #EarlyCancerDetection #ColorectalCancer #CancerScreening #BloodBasedTesting #Multiomics

We’re sharing new data this week at the @ASCO Gastrointestinal Cancers Symposium on the clinical performance of an updated version of Freenome’s SimpleScreen™ CRC screening blood test. In a large head-to-head case-control validation study, the updated test showed meaningful performance improvements over the first-generation assay, with CRC sensitivity at 85% and APL sensitivity at 22%. These advances reflect targeted upgrades across the assay, workflow, and automation, and reinforce the strength of Freenome’s multiomics discovery platform. These results build on the PREEMPT CRC Study and support our approach to systematically improving early cancer detection through thoughtful versioning of our technology. If you’re attending ASCO GI, stop by our poster session on Saturday, Jan. 10, at 7 am PT, to see the full data and learn more. Read the press release here: https://lnkd.in/gaNt3EjF #GI26 #EarlyCancerDetection #ColorectalCancer #CancerScreening #BloodBasedTesting #Multiomics

Freenome is thrilled to share a monumental step in our journey to redefine early cancer detection! We have signed a definitive business combination agreement (BCA) with Perceptive Capital Solutions Corp, a special purpose acquisition company (SPAC) sponsored by Perceptive Capital Solutions, which will position us to become a publicly traded company. This is a powerful endorsement of our science, our team and the massive market potential for multi-cancer screening.  Learn more about this exciting partnership and the future of early cancer detection in our press release: https://lnkd.in/gyek_SWw Upon closing, the combined company expects to list on Nasdaq under the ticker symbol “FRNM.” The business combination is expected to be completed in the first half of 2026. We will share updates as the process advances and as we work to establish blood-based early detection as a routine element of clinical care.

At Freenome, our mission to detect cancer early is powered by collaboration — across our teams, our partners, and the patients and providers who inspire our work every day. We’re thankful for the scientists, engineers, clinicians, and colleagues who bring dedication and compassion to everything they do, and for the broader community that believes in our mission to change the future of cancer detection. From all of us at Freenome, wishing you and your loved ones a healthy, peaceful, and joyful Thanksgiving. #Thanksgiving #Gratitude #EarlyCancerDetection #Freenome

Lung cancer remains the # 1 cause of cancer death in the United States—responsible for about one in five cancer deaths each year. Nearly 230,000 people will be diagnosed in 2025, and many cases are found only after symptoms appear, when treatment options are more limited and survival rates are lower.¹ Improving early detection can change that trajectory. At Freenome, we’re developing a blood-based lung cancer screening test through extensive R&D and our PROACT LUNG Study. By combining multiomics and machine learning with the simplicity of a blood draw, we aim to make early detection of lung cancer more accurate and accessible for more people. #LCAM #LungCancer #EarlyDetection #Screening #Freenome References: 1. Siegel RL et al. CA Cancer J Clin. 2025;75(1):10-45.

Following this week's Best Places to Work recognition from GenomeWeb, we wanted to share something special. Awards are meaningful, but the real story is the people behind them. This video brings together voices from across Freenome - R&D, engineering, operations, the lab - and you can hear what drives them: curiosity, care for patients, and genuine respect for the colleagues working beside them. It’s the culture told in their own words. Thank you to every Freenomer who shows up with purpose and heart. This is what makes Freenome a place where people do their best work.

Freenome’s blood-based colorectal cancer (CRC) screening test achieves an efficient balance of benefits and burdens for adults aged 45-75, according to our new research published in the Journal of the National Cancer Institute (JNCI). Using a modeling framework consistent with U.S. Preventive Services Task Force (USPSTF) analyses, the study compared the benefits, burdens and harms of blood-based CRC screening to current strategies. Results show that while colonoscopy remains the gold standard, annual blood testing provides an efficient balance of benefits and burdens, achieving outcomes comparable to contemporary stool-based screening. Importantly, the study also modeled real-world conditions — recognizing that nearly 60 million eligible Americans remain unscreened — and found that biennial or triennial blood-based testing could improve population-level outcomes by increasing screening participation. These findings support consideration of blood-based CRC screening, including at biennial and triennial intervals, for its potential to increase utilization and deliver net population benefit. This publication was a collaboration among investigators from Freenome, EmpiriQA, the NYU Grossman School of Medicine and the Kaiser Permanente Division of Research. Publication Link: https://lnkd.in/e2zNVyfx #JNCI #ColorectalCancer #CRCscreening #CancerScreening #BloodBasedTesting #EarlyDetection

We’re proud to share that GenomeWeb has recognized Freenome as a Best Place to Work for 2025. This honor is a direct reflection of the feedback from employees and the culture we’ve built together—one driven by purpose, respect, and the belief that great science happens when people feel valued and heard. The GenomeWeb profile highlights what makes Freenome unique: teams that collaborate across disciplines, leaders that listen, and a shared commitment to earlier cancer detection. But at the heart of it all are Freenomers, whose dedication and passion make this achievement possible. This recognition truly belongs to them. Read GenomeWeb’s full feature here: https://lnkd.in/gBTp_Ugt